IBRX FY 2021 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$934,000+54.4% YoY

Gross Profit

$934,000100.0% margin

Operating Income

-$330M-35361.9% margin

Net Income

-$347M-37129.6% margin

EPS (Diluted)

$-0.89

Cash Flow

Operating Cash Flow

-$274M

Free Cash Flow

-$308M

Stock-Based Comp.

$57M

Balance Sheet

Total Assets

$469M

Total Liabilities

$713M

Stockholders' Equity

-$242M

Cash & Equivalents

$181M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$934,000	$605,000	+54.4%
Gross Profit	$934,000	$605,000	+54.4%
Operating Income	-$330M	-$221M	-49.5%
Net Income	-$347M	-$222M	-56.3%